The stable outlook reflects S&P Global Ratings’ expectation that Amgen’s revenue and EBITDA will remain stable despite patent ...

Revolution Medicines reports positive data for KRAS-targeting cancer drug elironrasib, showing higher response rates vs Amgen ...

The table below is a review of notable updates that occurred in April 2025 for investigational products in development.

The leading Merkel Cell Carcinoma Companies such as ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte ...

DelveInsight’s Renal Cell Carcinoma Pipeline report depicts a robust space with 30+ active players working to develop 30+ ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

We came across a bullish thesis on Amgen Inc. (AMGN) on Substack by Magnus Ofstad. In this article, we will summarize the ...

Amgen (AMGN) stock in focus as its antibody drug Tepezza becomes U.K.'s first medicine for adults with moderate to severe ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Busch sold 1,000 shares of Amgen. The total transaction amounted to $279,690. As of Wednesday ...

BMS pledges $40B over five years to boost U.S. R&D, tech innovation, and pharmaceutical manufacturing under CEO Christopher ...

Investors reacted negatively to the news. The company’s stock fell more than 16% yesterday. It’s also a setback in ...